By Metavalis Inc. The veteran led deep tech firm taps the renowned regulatory strategist and PharmaVoice 100 Honoree to architect the compliance framework for its re-dosable genetic medicines and solid state neural preservation systems.
|
By Metavalis Inc. The veteran led deep tech firm defines a new standard for optical computing, initiating the development of a proprietary differentiable physics kernel to solve the Non Linear Schrödinger Equation.
|
By Metavalis Inc. Missouri Based Biotech Firm Reveals "Project AETHELGAARD"A Unified Physics Architecture capable of 1 Tbps Neural State Transfer and Geological Scale Data Preservation.
|
By Metavalis Inc. Elite Advisory Board Comprising Veterans from Moderna, NIH, and U.S. Defense Assembled to Guide Secure LNP Development in the Ozarks.
|
By Metavalis Inc. Data driven signal validates the company's "Failure Doctrine" operational model, positioning the Missouri based firm as a pre-seed outlier in the convergence of genomic medicine and optical computing.
|
By Metavalis Bioengineering firm recruiting founding advisors in Lipid Physics, Hepatology, and Regulatory Affairs to guide its Smart LNP 3.0 platform and Dec 24th IP filing.
|
By Next Move Strategy Consulting Next Move Strategy Consulting reports that the global Infectious Disease Diagnostics Market is projected to reach around USD 35 billion by 2030, expanding at a CAGR of approximately 10% from 2024 to 2030.
|
By DPI Research The global AI in biotechnology market was valued at USD 3.23 billion in 2024, and is expected to reach USD 14.97 billion by 2033, rising at a CAGR of 21.1% during the forecast period.
|
By Manhattan BioSolutions, Inc. Collaborative research between Manhattan BioSolutions and the Institute of Chemical Biology & Drug Discovery (ICB&DD) at Stony Brook University will advance next-generation ADC platform using novel TxD payloads
|
By NEXS Technology Group NEXS Technology Group is excited to announce its acceptance into the prestigious AWS Startup Program, a significant milestone that will propel the development and deployment of CancerScope-AI, our state-of-the-art artificial intelligence tool.
|
By NEXS BioMedica Corporation NEXS BioMedica, a forward-thinking biotech pharmaceutical company, proudly introduces CancerScope-AI, an innovative artificial intelligence system set to transform the battle against rare cancers.
|
By Manhattan BioSolutions, Inc. Manhattan BioSolutions, Inc. ("MABS"), an emerging biotechnology company developing new classes of precision biologics that harness natural host defense mechanisms, today announced that its RNA-targeting therapeutic, MABS-139, will be evaluated in...
|
By Maxis Clinical Sciences New Global Centre to Advance Clinical Research and Digital Innovation
|
